Yi-Ju Tseng1, Aurel Cami2, Donald A Goldmann3, Alfred DeMaria4, Kenneth D Mandl5. 1. Computational Health Informatics Program, Boston Children's Hospital. 2. Computational Health Informatics Program, Boston Children's Hospital Department of Pediatrics. 3. Department of Institute for Healthcare Improvement, Cambridge Division of Infectious Diseases, Boston Children's Hospital. 4. Bureau of Infectious Disease, Massachusetts Department of Public Health, Jamaica Plain. 5. Computational Health Informatics Program, Boston Children's Hospital Department of Pediatrics Department of Biomedical Informatics, Harvard Medical School, Boston.
Abstract
BACKGROUND: Most patients with Lyme disease (LD) can be treated effectively with 2-4 weeks of antibiotics. The Infectious Disease Society of America guidelines do not currently recommend extended treatment even in patients with persistent symptoms. METHODS: To estimate the incidence of extended use of antibiotics in patients evaluated for LD, we retrospectively analyzed claims from a nationwide US health insurance plan in 14 high-prevalence states over 2 periods: 2004-2006 and 2010-2012. RESULTS: As measured by payer claims, the incidence of extended antibiotic therapy among patients evaluated for LD was higher in 2010-2012 (14.72 per 100 000 person-years; n = 684) than in 2004-2006 (9.94 per 100 000 person-years; n = 394) (P < .001). Among these patients, 48.8% were treated with ≥2 antibiotics in 2010-2012 and 29.9% in 2004-2006 (P < .001). In each study period, a distinct small group of providers (roughly 3%-4%) made the diagnosis in >20% of the patients who were evaluated for LD and prescribed extended antibiotic treatment. CONCLUSIONS: Insurance claims data suggest that the use of extended courses of antibiotics and multiple antibiotics in the treatment of LD has increased in recent years.
BACKGROUND: Most patients with Lyme disease (LD) can be treated effectively with 2-4 weeks of antibiotics. The Infectious Disease Society of America guidelines do not currently recommend extended treatment even in patients with persistent symptoms. METHODS: To estimate the incidence of extended use of antibiotics in patients evaluated for LD, we retrospectively analyzed claims from a nationwide US health insurance plan in 14 high-prevalence states over 2 periods: 2004-2006 and 2010-2012. RESULTS: As measured by payer claims, the incidence of extended antibiotic therapy among patients evaluated for LD was higher in 2010-2012 (14.72 per 100 000 person-years; n = 684) than in 2004-2006 (9.94 per 100 000 person-years; n = 394) (P < .001). Among these patients, 48.8% were treated with ≥2 antibiotics in 2010-2012 and 29.9% in 2004-2006 (P < .001). In each study period, a distinct small group of providers (roughly 3%-4%) made the diagnosis in >20% of the patients who were evaluated for LD and prescribed extended antibiotic treatment. CONCLUSIONS: Insurance claims data suggest that the use of extended courses of antibiotics and multiple antibiotics in the treatment of LD has increased in recent years.
Authors: Natalie S Marzec; Christina Nelson; Paul Ravi Waldron; Brian G Blackburn; Syed Hosain; Tara Greenhow; Gary M Green; Catherine Lomen-Hoerth; Marjorie Golden; Paul S Mead Journal: MMWR Morb Mortal Wkly Rep Date: 2017-06-16 Impact factor: 17.586